教授，主任醫(yī)師，博士生導師，中央保健會診專家

北京大學第一醫(yī)院感染疾病科主任，兼任肝病中心主任

中華醫(yī)學會感染病學分會主任委員

中國醫(yī)院協(xié)會抗菌藥物合理應用工作委員會主任委員

中國醫(yī)師協(xié)會感染病醫(yī)師分會副會長

中華醫(yī)學會全科醫(yī)師教育學院副院長

國家免疫規(guī)劃專家咨詢委員會委員

國家衛(wèi)健委傳染病標準委員會委員

國家衛(wèi)健委新冠病毒肺炎醫(yī)療救治專家組成員

國家衛(wèi)健委新冠病毒肺炎恢復期血漿治療專家組成員

境外抗疫醫(yī)療專家組國家顧問團成員

國務院應對新冠病毒肺炎聯(lián)防聯(lián)控機制科研攻關(guān)專家組成員

科技部新冠肺炎國際合作專家組成員

美國《臨床感染病》雜志編委，《中華傳染病雜志》和《中華臨床感染病雜志》副總編輯， 《臨床肝膽病學》共同主編等。

Gui-Qiang Wang, MD

Professor, Chief physician

Chairman, Department of infectious diseases,

Director, Center for liver disease, Peking University first hospital;

President, Society of Infectious Diseases, Chinese Medical Association;

Chairman, Antimicrobial Stewardship Working Committee, Chinese hospital association;

Vice President, Infectious Disease Physicians Branch, Chinese Medical Doctor Association;

Vice President, General Practitioner Education College, Chinese Medical Association;

Member, National Immunization Program Expert Advisory Committee;

Member, National Health Commission Infectious Diseases Standards Committee;

Member, National Health Commission COVID-19 Medical Treatment Expert Group;

Member, National Health Commission COVID-19 Convalescent Plasma Therapy Expert Group;

Member, National Advisory Board of Overseas Anti-epidemic Medical Expert Group;

Member, The State Council Expert Group on Joint prevention and control mechanism of COVID-19;

Member, COVID-19 International Cooperation Expert Group, Ministry of Science and Technology

王貴強教授自COVID-19疫情爆發(fā)后，作為國家衛(wèi)生健康委員會醫(yī)療救治專家組成員，到安徽蚌埠和阜陽等地指導重癥和危重癥患者救治。參加中國COVID-19診斷和治療方案第五版、第六版和第七版的編寫和更新工作;參加恢復期血漿治療COVID-19治療方案的編寫工作。

受國家衛(wèi)生健康委員會和外交部委托，向世界各國(160余國家)介紹中國診斷和治療方案。多次參加國務院聯(lián)防聯(lián)控新聞發(fā)布會，介紹新冠肺炎診療方案更新，解答公眾和媒體的提問，進行科普宣教等。

主持國家科技部應急項目“法匹拉韋聯(lián)合托珠單抗治療新冠肺炎的多中心臨床研究”，主持“COVID-19恢復期患者核酸”復陽“發(fā)生機制、轉(zhuǎn)歸及治療干預的研究”等。

Since the outbreak of COVID 19, professor wang guiqiang, as a member of the medical treatment expert group of the national health commission, has guided clinical diagnosis and treatment, and participated in the compilation and update of the fifth, sixth and seventh version of the Chinese COVID 19 diagnosis and treatment protocol. Participated in the preparation of the convalescent plasma therapy protocol for COVID-19;

On behalf of the National Health Commission, he introduced China's diagnosis and treatment protocol to more than 160 countries in the world. On behalf of the National Health Commission, he participated in the press conferences of the state council on joint prevention and control for many times, presented the Protocol, answered questions from the public and the media, and explained COVID-19 prevention and control knowledge to the public.

Leading the emergency project of the ministry of science and technology "Favipiravir Combined Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study", and leading “The study on the mechanism, outcome and therapeutic intervention of COVID -19 convalescent patients that the nucleic acid reversion".